AI assistant
Acrivon Therapeutics, Inc. — Director's Dealing 2022
Nov 10, 2022
34507_dirs_2022-11-09_3c05a195-fa39-4cee-b499-2b2d0c4bd455.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Acrivon Therapeutics, Inc. (ACRV)
CIK: 0001781174
Period of Report: 2022-11-09
Reporting Person: Blume-Jensen Peter (Director, President and CEO)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 871857 | Direct |
| Common Stock | 293998 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.04 | 2031-01-13 | Common Stock (165947) | Direct | |
| Stock Option (Right to Buy) | $3.88 | 2032-04-05 | Common Stock (124460) | Direct | |
| Stock Option (Right to Buy) | $1.04 | 2031-01-13 | Common Stock (82973) | Indirect | |
| Stock Option (Right to Buy) | $3.88 | 2032-04-05 | Common Stock (62230) | Indirect |
Footnotes
F1: These securities are held by Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F2: Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2020, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
F3: The shares subject to the option vested or shall vest quarterly on the last day of each quarter for 16 quarters following January 1, 2022, in each case subject to the Reporting Person's continuous service through each such vesting date.